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Purpose: Many patients treated with stereotactic radiosurgery (SRS) alone as initial treatment
require 1 or more subsequent salvage therapies. This study aimed to determine if commonly used
salvage strategies are associated with differing risks of radiation necrosis (RN).
Methods and materials: All patients treated with upfront SRS alone for brain metastases at our
institution were retrospectively analyzed. Salvage treatment details were obtained for brain failures.
Patients who underwent repeat SRS to the same lesion were excluded. RN was determined based
on pathological conﬁrmation or advanced brain imaging consistent with RN in a symptomatic
patient. Patients were grouped according to salvage treatment and rates of RN were compared via
Fisher’s exact tests.
Results: Of 284 patients treated with upfront SRS alone, 132 received salvage therapy and 44
received multiple salvage treatments. This included 31 repeat SRS alone, 58 whole brain radiation
therapy (WBRT) alone, 28 SRS and WBRT, 7 surgery alone, and 8 surgery with adjuvant
radiation. With a median follow-up of 10 months, the rate of RN among all patients was 3.17%
(9/284), salvaged patients 4.55% (6/132), and never salvaged patients 1.97% (3/152). Receiving
salvage therapy did not signiﬁcantly increase RN risk (PZ .31). Of the patients requiring salvage
treatments, the highest RN rate was among patients that had both salvage SRS and WBRT
(delivered as separate salvage therapies) (6/28, 21.42%). RN rate in this group was
signiﬁcantly higher than in those treated with repeat SRS alone (0/31), WBRT alone (0/58),
surgery alone (0/7), and surgery with adjuvant radiation (0/8). Comparing salvage WBRT
doses <30 Gy versus 30 Gy revealed no effect of dose on RN rate. Additionally, amongConﬂicts of interest: None.
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RN incidence.
Conclusion: Our results suggest that initial management approach for recurrent brain metastasis
after upfront SRS does not affect the rate of RN. However, the risk of RN signiﬁcantly increases
when patients are treated with both repeat SRS and salvage WBRT. Methods to improve pre-
diction of toxicity and optimize patient selection for salvage treatments are needed.
Copyright ª 2016 the Authors. Published by Elsevier Inc. on behalf of the American Society for
Radiation Oncology. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction and rationale
Up to 40% of cancer patients develop brain metastases
each year in theUnited States, causing signiﬁcantmorbidity
and mortality.1 Much of the current literature focuses on
treatment approaches for brain metastases at initial diag-
nosis. For many patients stereotactic radiosurgery (SRS)
alone, deferring whole brain radiation therapy (WBRT),
has become a preferred strategy for small (<4 cm) metas-
tases and relatively favorable life expectancies.2-4
Phase 3 trials of SRS with or without WBRT for 1 to 3
metastases demonstrated that after SRS alone, local and
distant brain failures are approximately 10% to 30% and
40% to 70%, respectively.5-7 As systemic therapies
improve extracranial disease control, the number of pa-
tients who develop new and recurrent brain metastases is
likely to increase. Currently, there is no consensus on the
optimal treatment for patients with recurrent metastases.
Options often include supportive care, repeat SRS, sur-
gery, WBRT, or a combination of these approaches. The
evidence regarding the safety and efﬁcacy of the various
salvage treatments is very limited.8 The 2012 American
Society for Radiation Oncology brain metastases guide-
lines did not put forth any recommendations for man-
agement of recurrent brain metastases and identiﬁed this
topic as an area warranting further research.9
Given that many patients are treated with additional
radiation therapy in the setting of recurrent brain metas-
tases, it is important to consider the beneﬁts of treatment
against the risks. One of the most severe side effects of
brain radiation therapy is radiation necrosis (RN). The
aim of this study was to analyze current salvage practices
with respect to risk of developing RN for patients with
recurrent brain metastases after initial therapy with SRS.
We hypothesized that salvage SRS and/or WBRT under
current prescriptive paradigms do not signiﬁcantly in-
crease the rates of RN.
Methods and materials
With institutional review board approval, we retro-
spectively obtained data from electronic medical records
of patients treated with SRS alone for primarymanagement of brain metastases between 2001 and 2012.
Variables collected included patient age, gender, race,
Karnofsky performance status (KPS), tumor histology,
extracranial disease burden, as well as number and largest
diameter of both initial and recurrent brain metastases.
Radiation Therapy Oncology Group (RTOG) Recursive
Partitioning Analysis scores were calculated for each
patient.10 Treatment data including radiation modality,
prescription doses, and schedules were also obtained.
Initial and repeat SRS without planned WBRT was
generally offered for <5 brain metastases, each <4 cm, in
patients with KPS 70, and life expectancies 3 months.
If additional occult metastases were found at the time of
SRS, 5 lesions were sometimes treated with SRS with
or without WBRT. Patients who received SRS to the same
lesion multiple times were excluded given previously
demonstrated elevated risk of RN.11 WBRT was not
combined with initial or salvage SRS but was used as a
separate salvage therapy. Although there was no strict
standard for use of salvage WBRT, it was generally used
for patients with >4 active lesions, Eastern Cooperative
Oncology Group performance scale 2, or predicted life
expectancy of <3 months. Salvage surgery was typically
reserved for patients with large (>4 cm) or severely
symptomatic lesions.
SRS was performed using a Leksell Gamma Knife
Model C (Elekta AB, Stockholm, Sweden). The target
volume included the contrast-enhancing lesion with a 1 to
2 mm margin. Prescription doses were generally based on
tumor size according to RTOG study 90-05.12 Prescrip-
tion doses for salvage WBRT ranged from 20 to 37.5 Gy
in 10 to 15 fractions.
Patients were seen in follow-up approximately 1
month after treatment and every 3 months thereafter.
Magnetic resonance imaging scans were obtained at each
scheduled visit. The primary outcome measure for this
study was rate of RN. RN was either conﬁrmed by pa-
thology after surgical resection or deﬁned as a symp-
tomatic patient with magnetic resonance spectroscopy or
perfusion results consistent with necrosis. Patients were
grouped according to salvage treatment received. Poten-
tial variables affecting incidence of necrosis were
compared via Fisher’s exact tests. Two-sided P values
<.05 were considered statistically signiﬁcant.
Table 1 Patient demographics at initial SRS
Variable Category All patients
(N Z 284)
Salvaged patients
(N Z 132)
Never salvaged
patients (N Z 152)
Sex Male 130 (46%) 58 (44%) 71 (47%)
Female 154 (54%) 74 (56%) 81 (53%)
Age at ﬁrst SRS Median 61.6 59.7 63.5
Histology Non-small cell lung 174 (61%) 84 (64%) 90 (59%)
Breast 32 (12%) 23 (17%) 9 (6%)
Melanoma 20 (7%) 8 (6%) 12 (8%)
Colon 7 (2%) 3 (2%) 4 (3%)
Other 51 (18%) 14 (11%) 37 (24%)
RPA class 1 69 (25%) 44 (33%) 31 (20%)
2 187 (66%) 69 (52%) 111 (73%)
Unknown 25 (9%) 15 (11%) 7 (5%)
Number of lesions Average 3 3 2
Range 1-14 1-12 1-14
Maximum lesion size, cm3 Average 9.87 6.20 7.66
Range 0.1-93.29 0.27-93.29 0.27-64.45
Prescription dose (minimum dose
delivered to largest met), Gy
Average 18.63 18.37 18.91
Range 12-22 12-22 12-22
RPA, recursive partitioning analysis; SRS, stereotactic radiosurgery.
Figure 1 Effect of salvage treatment on radiation necrosis
(RN) incidence.
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A total of 284 patients with 677 total brain metastases
treated with initial SRS alone were included. The de-
mographic data for these patients are presented in Table 1.
No salvage treatments were delivered to 152 patients
(53.5%), whereas 132 patients (46.5%) experienced in
brain failure and received salvage therapy. Forty-four
(15.5%) received multiple salvage treatments. Of the
salvaged patients, 31 (23.5%) underwent 1 or more SRS
treatments without WBRT, 58 (43.9%) WBRT alone, 28
(21.2%) SRS and WBRT delivered as separate salvage
therapies, 7 (0.5%) underwent surgery alone, and 8
(0.6%) surgery with adjuvant radiation (5 adjuvant SRS, 3
adjuvant WBRT).
With a median follow-up of 10 months, the rate of
RN among all patients was 3.17% (9/284), never
salvaged patients 1.97% (3/152), and salvaged patients
4.55% (6/132). RN was conﬁrmed by pathology in 7/9
(78%) of these patients, and suggested by symptom-
atology and magnetic resonance spectroscopy or perfu-
sion in 2/9 (22%) patients. Receiving salvage therapy
did not signiﬁcantly increase risk of RN (P Z .31).
These data are depicted in Fig 1.
Subgroup analysis according to salvage approach
revealed the highest rate of necrosis in patients that had
both salvage SRS and salvage WBRT (6/28 or 21.42%).
RN in this group was signiﬁcantly more frequent than
those receiving no salvage therapy (3/152, P < .001),
salvage SRS alone (0/31, P < .001), and salvage WBRT
alone (0/58, P < .001). The RN rate was not signiﬁcantly
greater than that in patients who underwent salvagesurgery alone (0/7, P Z .311), or salvage surgery with
adjuvant radiation (0/8, P Z .302), likely because of
small sample sizes in these groups. RN incidence between
patients that underwent salvage SRS alone and salvage
WBRT alone was also not signiﬁcantly different
(P Z 1.0). These data are graphed in Fig 2.
To assess whether dose of salvage WBRT contributed
to rate of RN, patients that received doses of <30 Gy
were compared with those that received 30 Gy. No
signiﬁcant effect of dose on incidence of RN was found
(P Z .181). Additionally, among patients who received
multiple SRS treatments, number of treated lesions was
not predictive of RN incidence (PZ .3982). Size analysis
in this population revealed no signiﬁcant effect of volume
of largest met <5 cm3 versus 5 cm3 on incidence of RN
(P Z .4168.) Patients who received SRS for >4 cumu-
lative lesions had a risk of RN of 12.8%, whereas patients
Figure 2 Incidence of RN by salvage modality. RN, radiation
necrosis; SRS, stereotactic radiosurgery; WBRT, whole brain
radiation therapy.
Table 2 Comparative analysis of salvage treatments and
associations with risk of radiation necrosis
Group OR for RN with
95% CI
P
value
Any salvage vs no salvage 2.37 (0.56-9.65) .31
Salvage SRS vs any salvage 2.32 (0.72-7.49) .21
Salvage WBRT vs any salvage 1.59 (0.49-5.09) .55
Salvage surgery vs any salvage 0.63 (0.03-11.69) .76
Any salvage vs salvage
SRS þ WBRT
5.73 (1.69-19.38) .0075
Salvage SRS vs salvage
SRS þ salvage WBRT
18.2 (0.98-339.79) .05
Salvage WBRT vs salvage
SRS þ salvage WBRT
3.77 (1.11-12.85) .04
Salvage SRS alone vs salvage
WBRT alone
1.86 (0.034-95.86) .31
Subgroups
All salvage WBRT dose
30 vs <30
4 (0.69-23.23) .18
All SRS lesions >4 vs 1-4 3.24 (0.35-29.58) .39
Bold font indicates P < .05.
CI, conﬁdence interval; RN, radiation necrosis; OR, odds ratio; SRS,
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These data are depicted in Fig 3. Primary and subgroup
comparisons are given in Table 2.stereotactic radiosurgery; WBRT, whole brain radiation therapy.Discussion
Limited data exist to guide salvage treatment decisions
for patients with recurrent brain metastases after initial
management with SRS alone. Management is typically
individualized and based on a variety of factors including
patient KPS, extracranial disease status, prior treatment
history, and recurrent lesion size, number, timing, and
location.13 Given that many of these patients are treated
with multiple courses of radiation therapy (ie, repeat SRS
and/or salvage WBRT), risk of additional radiation-
related toxicity must be considered.
The present study investigated risk of RN, the most
common and serious late complication after SRS. RN is
permanent brain injury that manifests 3 months to several
years after treatment. Although the exact pathogenesis of
RN is unknown, it is thought to involve release of pro-
inﬂammatory cytokines, vascular damage, and directFigure 3 Risk of RN by cumulative dose. Abbreviations as in
Fig 2.toxicity to neuroglia.14,15 In the absence of invasive
pathological conﬁrmation, RN is often difﬁcult to distin-
guish from temporary adverse radiation effects (ARE) and
tumor progression. Both RN and tumor recurrence can
cause progressive clinical deterioration and death.16
Advanced magnetic resonance imaging sequences, mag-
netic resonance spectroscopy, and magnetic resonance
perfusion are most commonly used to help differentiate
RN from recurrent tumor.17-19 Our group deﬁned RN by
pathology after resection or symptomatic ARE with
magnetic resonance spectroscopy and/or perfusion
consistent with RN. With this deﬁnition, the incidence of
RN in our entire cohort of SRS treated patients was 3%.
This is consistent with other studies which have demon-
strated RN risk of approximately 5% after SRS for brain
metastases.20,21
The incidence of RN is directly related to total radia-
tion dose, volume, and fraction size.22-32 RTOG 90-05
established that for patients who had previously received
irradiation for primary brain tumors or brain metastases,
maximum tolerated dose of single-fraction SRS was 24
Gy, 18 Gy, and 15 Gy for tumors 20 mm, 21 to 30 mm,
and 31 to 40 mm in maximum diameter, respectively,
with larger tumor diameter predictive of greater central
nervous system (CNS) toxicity.12 Incidence of RN in
RTOG 90-05 was 5% at 6 months after SRS, and
increased incrementally with time thereafter, up to 11% at
24 months.33 In the setting of SRS without WBRT, the
volumes of CNS tissue that receives 10 and 12 Gy have
been consistently shown to correlate with risk of
RN.23,28,34 In addition to 10- and 12-Gy volumes, Sneed
et al identiﬁed capecitabine/ﬂuorouracil use within 1
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pendent predictors of ARE after SRS. For locally recur-
rent metastases treated with repeat SRS, the risk of
symptomatic ARE was approximately 20% at 1 year.35 A
rate of 19% was seen for patients treated repeat SRS to the
same lesion.11 We therefore excluded these patients from
our study. We hypothesized, however, that other salvage
practices under current prescriptive paradigms would not
be associated with elevated risk of RN given that SRS
doses used were established by RTOG 90-05, which, as
previously noted, determined maximum tolerated SRS
dose in previously irradiated patients.12
As predicted, we found that after initial SRS, treating
recurrences with salvage SRS alone, WBRT alone, or
surgery with adjuvant radiation were not associated with
increased risk of RN. However, when repeat SRS was
combined with WBRT, more than 20% of patients
developed RN. This increased risk of RN is likely due to
relatively higher radiation doses to larger volumes of
normal brain tissue in these patients. Our results, thus,
suggest that if a patient is felt to likely need salvage
WBRT, combining this with additional SRS treatments
might have risks that outweigh the beneﬁts of repeat SRS.
Therefore, it would be useful to estimate risk of regional
recurrence and likelihood for future salvage WBRT
before offering patients repeat SRS.
Multiple tools have been developed that predict for
overall survival in patients with brain metastases.10,36-38
The Graded Prognostic Assessment has recently been
shown to also predict survival in the salvage SRS setting.39
Variables, such as patient age, KPS, cancer histology,
number of metastases, and systemic disease status, which
predict for regional brain failure and WBRT-free survival
after initial SRS, are also likely useful in the context of
salvage treatments.40-43 In our study, only 30% (86/284) of
patients treated with upfront SRS required salvage WBRT;
however, a signiﬁcant portion of patients (47.5%; 28/59)
treated with repeat SRS eventually needed WBRT.
Methods are needed to optimize patient selection for
salvage SRS to avoid treating patients that will require early
WBRT with its associated toxicities.
The interpretation of our results is limited by the
retrospective nature and nonrandomized study design,
which introduces multiple well-described biases in data
collection and analysis.44 This could have led to the un-
derestimation of incidence of RN in our patient popula-
tion. Additionally, the generalizability of our results is
dependent on how one deﬁnes RN. In patients without
surgical removal of necrotic tissue, we had a high
threshold to consider radiographic ﬁndings as consistent
with RN. It is possible that some patients with RN were
not identiﬁed because of loss of follow-up or because
magnetic resonance spectroscopy or perfusion studies
were simply not obtained. More accurate methods of
distinguishing RN from temporary ARE or tumor pro-
gression is an area of active research.Conclusion
Our results suggest that initial management approach
for recurrent brain metastasis after upfront SRS alone
does not affect the rate of subsequent RN. However, when
patients are treated with repeat SRS and salvage WBRT,
risk of RN signiﬁcantly increases. When faced with
recurrent brain metastases, patient and disease factors, as
well as likelihood of requiring additional salvage treat-
ment, are important considerations when estimating po-
tential beneﬁts and risks of therapy.
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